Table 2.
Correlation of VISTA on immune cells and other immune markers in TNBC.
| Markers | VISTA on immune cells | ||||||
|---|---|---|---|---|---|---|---|
| Negative | Positive | p value | |||||
| N | % | N | % | N | % | ||
| TILs | <0.001 | ||||||
| < 5% | 143 | 56.3 | 77 | 69.4 | 66 | 46.2 | |
| ≥ 5% | 111 | 43.7 | 34 | 30.6 | 77 | 53.8 | |
| CD3 | 0.009 | ||||||
| < 20% | 125 | 49.2 | 65 | 58.6 | 60 | 42 | |
| ≥ 20% | 129 | 50.8 | 46 | 41.4 | 83 | 58 | |
| CD4 | <0.001 | ||||||
| < 10% | 104 | 40.9 | 67 | 60.4 | 37 | 25.9 | |
| ≥ 10% | 150 | 59.1 | 44 | 39.6 | 106 | 74.1 | |
| CD8 | 0.021 | ||||||
| < 10% | 121 | 47.6 | 62 | 55.9 | 59 | 41.3 | |
| ≥ 10% | 133 | 52.4 | 49 | 44.1 | 84 | 58.7 | |
| CD19 | <0.001 | ||||||
| < 1% | 115 | 45.3 | 75 | 67.6 | 40 | 28 | |
| ≥ 1% | 139 | 54.7 | 36 | 32.4 | 103 | 72 | |
VISTA, V-domain Ig suppressor of T-cell activation; TNBC, triple-negative breast cancer; TIL, tumor-infiltrating lymphocyte.